<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neuronal ceroid lipofuscinosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neuronal ceroid lipofuscinosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neuronal ceroid lipofuscinosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erika F Augustine, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Mink, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 19, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2185621369"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The neuronal ceroid lipofuscinoses (NCLs) are a group of lysosomal diseases characterized by progressive neurodegeneration and intracellular accumulation of autofluorescent lipopigment.</p><p>This topic will review the NCLs.</p><p class="headingAnchor" id="H33466395"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span></p><p class="headingAnchor" id="H2880656688"><span class="h2">History and eponyms</span><span class="headingEndMark"> — </span>The first description of an NCL in the western medical literature was by Stengel [<a href="#rid1">1</a>], who described a childhood-onset disorder with blindness and progressive dementia. A similar clinical entity was described by Batten in 1903 and included the first description of neuropathology: "cerebral degeneration with macular changes" [<a href="#rid2">2</a>]. Similar reports were made by Spielmeyer [<a href="#rid3">3</a>] and Vogt [<a href="#rid4">4</a>]<sup> </sup>in 1905. This disorder has come to be known as juvenile NCL, Batten-Spielmeyer-Vogt disease, or simply Batten disease. Shortly thereafter, Janský [<a href="#rid5">5</a>] and Bielschowsky [<a href="#rid6">6</a>] described a similar disorder with "late infantile" onset, which became known as late infantile NCL or Janský-Bielschowsky disease. Kufs later described an adult-onset disease with similar pathology but lacking visual impairment [<a href="#rid7">7</a>], eventually called adult-onset NCL or Kufs disease. In the 1970s, an infantile-onset form was reported by Haltia [<a href="#rid8">8</a>] and Santavuori [<a href="#rid9">9</a>], which became known as infantile NCL or Haltia-Santavuori disease.</p><p class="headingAnchor" id="H3446712132"><span class="h2">Classic forms</span><span class="headingEndMark"> — </span>The NCLs were originally diagnosed based on clinical features and ultrastructural abnormalities found with electron microscopy and were grouped into four classic forms:</p><p class="bulletIndent1"><span class="glyph">●</span>Infantile NCL (Haltia-Santavuori disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Late infantile NCL (Janský-Bielschowsky disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Juvenile NCL (Batten-Spielmeyer-Vogt disease, or simply Batten disease)</p><p class="bulletIndent1"><span class="glyph">●</span>Adult NCL (Kufs disease)</p><p></p><p>Each of the four classic forms was formerly thought to have distinct ultrastructural findings, with granular osmiophilic deposits in infantile NCL, curvilinear profiles in late infantile NCL, fingerprint bodies in juvenile NCL, and rectilinear profiles in adult NCL [<a href="#rid10">10</a>]. However, as the genetic basis of each NCL emerged and genetic testing became standard, it is now apparent that the relationship between genotype or NCL type and ultrastructural features is not specific.</p><p>Over time, investigators have described additional forms of NCL with clinical features similar to those of the four classic forms.</p><p class="headingAnchor" id="H635307118"><span class="h2">Definition and modern classification</span><span class="headingEndMark"> — </span>With new proposed NCL genes and an expanding number of associated clinical entities, it became necessary to develop a clear definition of NCL: "a progressive degenerative disease of the brain and, in most cases, the retina, in association with intracellular storage of material that is morphologically characterized as ceroid lipofuscin or similar" [<a href="#rid11">11</a>].</p><p>NCL experts now recommend primary disease classification by gene or protein (eg, CLN1 disease or PPT1 deficiency) and secondary classification by age at onset and clinical features. A more extensive proposed classification system includes seven axes: 1) affected gene (<em>CLN</em> gene symbol), 2) mutation diagnosis, 3) biochemical phenotype, 4) clinical phenotype, 5) ultrastructural features, 6) level of functional impairment (descriptive or using a universally recognized scoring system), and 7) other remarks (additional genetic, environmental, or clinical features) [<a href="#rid12">12</a>].</p><p>Although comprehensive, the seven axis system is impractical for regular clinical use; the authors suggest axes 1 (gene or protein) and 4 (clinical phenotype) for clinical practice [<a href="#rid12">12</a>].</p><p>Despite efforts to standardize nomenclature, multiple interchangeable terms remain in use. Thus, Batten disease may be used to refer specifically to CLN3 disease or as an umbrella term for all NCLs. Infantile NCL (INCL) may be used interchangeably with CLN1 disease; late infantile NCL (LINCL) may be used interchangeably with CLN2 disease; and juvenile NCL (JNCL) may be used interchangeably with CLN3 disease. Several forms may be referred to as variant late infantile NCL (vLINCL). In what follows, we will adhere to the classification system proposed by Williams and Mole [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H1780907949"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Abnormal intracellular storage materials accumulate in all NCL disorders, comprised of a mixture of lipids and proteins. The main storage material composition includes saposins in CLN1, CLN10, and CLN11 diseases, with mitochondrial adenosine triphosphate (ATP)-synthase subunit C in most forms including CLN11 disease [<a href="#rid13">13</a>]. There is typically early, regional glial activation and functional impairment preceding neuronal loss [<a href="#rid14">14,15</a>]. Though NCL genes are expressed widely outside of the nervous system in various tissues, disease manifestations primarily derive from central nervous system dysfunction. There appears to be both regional and cell-type specific selective vulnerability to NCL protein deficiency, with early retinal degeneration as a prominent feature in some forms and later or no known involvement of the retina in others. The thalamus and cerebellum are affected early in many NCL forms [<a href="#rid16">16</a>].</p><p>Distinct inclusion patterns (fingerprint, curvilinear profiles, granular osmiophilic deposits) are found in multiple tissues, including skin, rectal tissue, brain, and smooth muscle  (<a class="graphic graphic_picture graphicRef127496" href="/d/graphic/127496.html" rel="external">picture 1</a>). Inclusion patterns, once thought to represent distinct forms of NCL, are now recognized to have overlap across genetic etiologies, and multiple inclusion patterns can be observed within a single genetic cause [<a href="#rid17">17-19</a>]. Emerging knowledge suggests interactions between certain NCL genes [<a href="#rid20">20-23</a>]. In CLN3 disease, an additional pathologic finding of vacuolated lymphocytes  (<a class="graphic graphic_picture graphicRef127234" href="/d/graphic/127234.html" rel="external">picture 2</a>) can be an important clue to diagnosis [<a href="#rid24">24</a>].</p><p>Five forms of NCL are due to defects in soluble lysosomal proteins: CLN1 disease due to palmitoyl protein thioesterase-1 deficiency, CLN2 disease due to tripeptidyl peptidase-1 deficiency, CLN5 disease due to bis(monoacylglycero)phosphate (BMP) deficiency [<a href="#rid25">25</a>], CLN10 disease due to cathepsin D deficiency, and CLN13 due to cathepsin F deficiency.</p><p>All other known forms of NCL are caused by defects in lysosomal, endoplasmic reticulum, or cytoplasmic vesicular transmembrane proteins [<a href="#rid26">26,27</a>].</p><p>Though the specific pathways underlying involvement in protein dysfunction, lysosomal storage, and neuronal death are still being investigated, putative roles in cellular function include regulation of lysosomal acidification [<a href="#rid28">28,29</a>], lysosomal sorting [<a href="#rid30">30</a>], regulation of autophagy [<a href="#rid31">31</a>], calcium homeostasis, and galactosylceramide transport [<a href="#rid32">32</a>], along with other cellular homeostasis functions [<a href="#rid16">16,27</a>].</p><p>Other diseases have been identified that show evidence of intracellular ceroid lipofuscin accumulation. Debate remains as to whether these are indeed true NCLs [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1754630123"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>At least 13 different genetic forms of NCL have been identified and assigned a "CLNx" number. Genetic forms of NCL are summarized in the table  (<a class="graphic graphic_table graphicRef127080" href="/d/graphic/127080.html" rel="external">table 1</a>). With the exception of CLN4 disease, the NCLs are recessive disorders.</p><p>As we gain more knowledge about the spectrum of disease associated with NCLs, it has become apparent that causative gene and specific pathogenic variants do not always predict phenotype. In addition, though there are general phenotypic patterns, including age at onset, which guide the diagnostic approach, age at onset does not necessarily predict genotype. There is also now an established association between haploinsufficiency of the progranulin (<em>GRN</em>) gene and adult-onset frontotemporal dementia, which may be relevant for family genetic counseling [<a href="#rid13">13,34</a>].</p><p class="headingAnchor" id="H1783067559"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Collectively, NCLs are the most prevalent neurodegenerative disorders of childhood [<a href="#rid11">11</a>]. However, the individual NCLs are rare conditions, epidemiologic studies are limited, and prevalence estimates vary from country to country, in part due to founder effects for certain disease forms.</p><p>In Europe, where the majority of epidemiologic studies have been conducted, incidence estimates range from 0.6 per 100,000 in Italy to 13.6 per 100,000 in Newfoundland [<a href="#rid35">35-37</a>]. Collectively, NCLs have an estimated prevalence of 1 per 1 million people in the United States [<a href="#rid38">38</a>], 1.2 per 1 million people in Italy [<a href="#rid36">36</a>], and as high as 1 per 100,000 people in Scandinavian regions [<a href="#rid38">38</a>]. In Latin America, CLN2 and CLN3 diseases represent the most prevalent NCL forms [<a href="#rid39">39</a>]. Worldwide, as the number of recognized NCL types has increased and as the approach to diagnostic testing has evolved, there is a need for updated assessment of the incidence and prevalence of NCL disorders.</p><p class="headingAnchor" id="H481818820"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3477627172"><span class="h2">Shared features</span><span class="headingEndMark"> — </span>The NCLs share features of a progressive clinical course with vision loss, dementia, epilepsy, movement disorders, and storage of ceroid lipofuscin in neurons. Despite similar features, each NCL is a distinct biologic entity and differs from other NCLs in age at onset, specific clinical features, rate of progression, or a combination of these factors [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H4037129008"><span class="h2">Individual genetic forms</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN1 disease</strong> – The <em>CLN1</em> gene codes for palmitoyl-protein thioesterase-1 (PPT1), a soluble lysosomal protein [<a href="#rid41">41</a>]; pathogenic variants in <em>CLN1</em> are generally associated with classic infantile NCL. In classic infantile-onset CLN1 disease, following a period of normal-appearing development, there is rapid developmental regression between 6 and 24 months of age, combined with seizures, myoclonus, ataxia, and visual failure [<a href="#rid42">42</a>]. Visual failure usually occurs by age 2 years with optic atrophy, retinal changes, and early extinction on the electroretinogram. Signs and symptoms progress to a state of severe spasticity and decreased level of consciousness; lifespan is severely shortened.</p><p></p><p class="bulletIndent1">Some pathogenic variants in <em>CLN1</em> can cause later onset disease with more extended disease courses. All forms of childhood-onset CLN1 disease progress to premature death, though typically, the later the symptom onset, the more protracted the course. Late infantile CLN1 disease begins between two and four years of age. There is visual and cognitive decline followed by development of ataxia and myoclonus [<a href="#rid43">43,44</a>]. Juvenile CLN1 disease, also referred to as "juvenile NCL with granular osmiophilic deposits," typically presents between the ages of 5 and 10 years, with cognitive decline followed by epilepsy, motor decline, and vision loss [<a href="#rid44">44,45</a>]. There are case reports of a rare adult-onset form, beginning with cognitive decline and depression, followed by ataxia, parkinsonism, and vision loss [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1">In terms of genotype-phenotype correlations, pathogenic variants predicted to cause severe truncation or loss of protein are more likely to be associated with infantile-onset disease [<a href="#rid44">44,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN2 disease</strong> – The <em>CLN2</em> gene codes for tripeptidyl peptidase-1 (TPP1), a soluble lysosomal protein, and is associated with the classic late infantile-onset form of NCL [<a href="#rid49">49</a>]. CLN2 disease is more homogeneous than CLN1 disease in age at onset and clinical phenotype, though some variability still exists. Classic late infantile CLN2 disease presents between two and four years of age [<a href="#rid50">50</a>]. Typically, there is speech delay, developmental plateau, or loss of developmental milestones beginning in the second year of life, followed by the development of refractory epilepsy [<a href="#rid51">51</a>]. Seizures are polymorphic and include myoclonic, tonic, atypical absence, and tonic clonic. Over time, ataxia, refractory nonepileptic myoclonus, and spastic quadriparesis develop. Due to substantial cognitive impairment, vision loss may be less obvious than in other forms of NCL. Retinal degeneration is most apparent in the macula, but there is no "cherry red spot" [<a href="#rid52">52</a>]. Electroretinograms and visual-evoked potentials are abnormal.</p><p></p><p class="bulletIndent1">As with CLN1 disease, children with onset of CLN2 disease after the age of four years tend to have a milder course with more prominent ataxia and less prominent epilepsy [<a href="#rid53">53,54</a>]. Later onset is typically associated with reduced levels, but not absence, of functional TPP1 enzyme [<a href="#rid53">53</a>]. An even later onset variant has been called autosomal recessive spinocerebellar ataxia 7 (SCAR7) based on the absence of epilepsy and vision loss, but this entity has now been shown to be caused by TPP1 deficiency due to pathogenic variants in <em>CLN2</em> [<a href="#rid55">55,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN3 disease</strong> – The <em>CLN3</em> gene encodes a lysosomal transmembrane protein of unknown function and is associated with the classic juvenile-onset form of NCL. There appears to be less phenotypic heterogeneity for CLN3 disease than in other forms of NCL; a single phenotype predominates [<a href="#rid57">57,58</a>]. The typical age at onset in CLN3 disease is between four and seven years, with vision loss that rapidly progresses from normal vision to functional blindness over the course of approximately one year. Light-dark perception may be retained for several years. Vision loss is followed by cognitive decline, behavioral problems, epilepsy, and parkinsonism [<a href="#rid59">59-61</a>]. CLN3 disease is also accompanied by a characteristic severe, stuttering dysarthria that usually develops after age 10 years. Females have slightly later onset of vision loss but also more rapid progression than males [<a href="#rid59">59,62</a>]. Cardiac conduction and structural abnormalities have been reported in older individuals [<a href="#rid63">63,64</a>].</p><p></p><p class="bulletIndent1">Less common phenotypes of CLN3 disease include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protracted CLN3 disease, characterized by slower progression, milder symptoms, or later onset of salient disease features compared with classic CLN3 disease [<a href="#rid65">65,66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonsyndromic retinal dystrophy but without other clinical features of an NCL [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autophagic vacuolar myopathy with cardiomyopathy, retinal dystrophy, and relative cognitive and motor function preservation [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN4 disease</strong> – CLN4 disease, an adult-onset NCL, is due to pathogenic variants in the <em>DNAJC5</em> gene that codes for a cysteine string protein [<a href="#rid69">69,70</a>]. This is the only known autosomal dominant form of NCL. CLN4 disease is also known as "Parry disease," named after the family in which it was first described [<a href="#rid71">71</a>]. Clinical features include ataxia, progressive dementia, seizures, and myoclonus, typically starting after 30 years of age. There is no vision loss associated with CLN4 disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN5 disease</strong> – CLN5 disease is a "variant" late infantile-onset form of NCL. The term "variant late infantile" has been used to distinguish forms with early childhood onset from classic late infantile CLN2 disease. CLN5 disease is sometimes referred to as the "Finnish variant" due to its initial description in Finland [<a href="#rid72">72</a>], but it is not limited to individuals with Finnish heritage [<a href="#rid73">73</a>]. The CLN5 protein is a soluble lysosomal glycoprotein of unknown function. The age at onset in CLN5 disease varies from 2 to 17 years, with a median of 5 years [<a href="#rid73">73,74</a>]. In a European cohort of 15 children with CLN5 disease, impaired learning and cognition were the most common early symptoms. Seizures occurred relatively late (median age 8 years). Other clinical features include psychomotor regression, ataxia, and visual failure, which may be a presenting sign. Atypical forms, with onset of vision loss, ataxia, and cerebellar atrophy in adulthood, have also been reported [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN6 disease</strong> – There are several phenotypes associated with <em>CLN6 </em>mutations. CLN6 disease was initially described as another variant late infantile-onset NCL [<a href="#rid76">76</a>]. Pathogenic variants in the <em>CLN6</em> gene have also been shown to cause classic late infantile-onset NCL and adult-onset type A Kufs disease [<a href="#rid17">17,77</a>]. The CLN6 protein is a transmembrane protein of unknown function. Like other "variant" late infantile-onset NCLs, the age at onset of childhood CLN6 disease is highly variable, ranging from 18 months to 8 years. Seizures are an early feature in CLN6 disease, occurring before five years in &gt;60 percent of patients. Early vision loss is reported in 50 percent of patients with CLN6 disease, but vision loss is not ubiquitous in late infantile CLN6 disease [<a href="#rid78">78</a>]. Additional clinical features include developmental delay, dysarthria, and ataxia [<a href="#rid76">76,79</a>]. There is rapid symptom progression, and death usually occurs between 5 and 12 years of age in early childhood-onset forms.</p><p></p><p class="bulletIndent1">As noted above, pathogenic variants in <em>CLN6</em> have been shown to cause autosomal recessive type A Kufs disease. Kufs disease has been subclassified as types A and B [<a href="#rid33">33</a>]. Type A begins with a progressive myoclonic epilepsy with later development of dementia and ataxia. In one series of 20 individuals with type A Kufs disease due to pathogenic variants in <em>CLN6</em>, the mean age at onset was 28 years (range 12 to 51 years) following a period of normal development. The initial symptom is typically refractory myoclonic seizures [<a href="#rid17">17</a>]. Visual symptoms are atypical in type A Kufs due to <em>CLN6</em> pathogenic variants. Ataxia leading to impaired walking, variable dementia, and dystonia may follow the onset of epilepsy; life span is shortened.</p><p></p><p class="bulletIndent1">Kufs type B (ie, CLN13) is characterized by dementia with cerebellar and/or extrapyramidal motor symptoms and has been attributed to pathogenic variants in the cathepsin F<em> </em>(<em>CTSF</em>) gene [<a href="#rid80">80</a>], as reviewed below in CLN13.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN7 disease</strong> – CLN7 disease is another "variant" late infantile-onset NCL, which is sometimes called the "Turkish" variant due to its initial description in Turkish families [<a href="#rid81">81</a>]. However, it is not limited to individuals with Turkish ancestry [<a href="#rid82">82</a>]. The CLN7 protein is a lysosomal membrane protein that belongs to the "major facilitator" superfamily of transporter proteins (major facilitator superfamily domain-containing 8 protein), and the encoding gene is <em>MFSD8</em>. Age at onset is typically between two and seven years. Seizures are typically an early sign, followed by motor decline, myoclonus, dementia, and vision loss.</p><p></p><p class="bulletIndent1">Pathogenic variants in <em>MFSD8 </em>have also been shown to cause a nonsyndromic, retinal rod-cone dystrophy with severe macular involvement. The specific pathogenic variants p.Glu336Gln and p.Met454Thr appear to be responsible for this phenotype [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN8 disease</strong> – CLN8 disease is caused by pathogenic variants in the <em>CLN8</em> gene encoding a transmembrane protein of the endoplasmic reticulum of unknown function. There are two recognized forms of the disease, but these may fall on a spectrum rather than representing two distinct phenotypes [<a href="#rid84">84</a>]. The first is a "variant" late infantile NCL that was initially described in Turkish families [<a href="#rid85">85</a>]<sup> </sup>but has also been reported in other ethnic groups [<a href="#rid86">86,87</a>]. Age of onset is usually 5 to 10 years; patients initially present with seizures followed by progressive motor and cognitive decline. Vision loss also occurs. The second form of CLN8 disease has been referred to as "Northern epilepsy," a form of progressive myoclonus epilepsy [<a href="#rid88">88,89</a>]. It is also characterized by seizures with cognitive and motor decline but without vision loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN9 disease</strong> – CLN9 disease was proposed as a distinct entity with a juvenile-onset NCL that was not CLN3 disease in two Serbian sisters and two German brothers [<a href="#rid90">90</a>]. A specific gene was not identified, and subsequently, it was determined that these individuals had pathogenic variants in <em>CLN5</em> [<a href="#rid91">91</a>]. Thus, CLN9 disease has not been confirmed to be a distinct entity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN10 disease</strong> – CLN10 disease can manifest as a severe congenital form of NCL or as a juvenile-onset form. CLN10 disease is caused by pathogenic variants in the lysosomal aspartic protease cathepsin D gene (<em>CTSD</em>) [<a href="#rid92">92</a>]. The congenital phenotype is the earliest onset form of NCL. It presents in the neonatal period with microcephaly, severe brain atrophy, absence of neonatal reflexes, and respiratory insufficiency. Infants with CLN10 disease rarely survive more than a few days. The juvenile-onset phenotype of CLN10 disease is characterized by onset of a progressive ataxia between ages 7 and 15 years, with associated pigmentary retinopathy and progressive cognitive decline. A sensory axonal neuropathy has also been described in some individuals [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN11 disease</strong> – CLN11 disease is due to pathogenic variants in the progranulin (<em>GRN</em>) gene [<a href="#rid34">34</a>]. Heterozygous pathogenic variants in <em>GRN</em> are a major cause of frontotemporal lobar degeneration in adults, but homozygous pathogenic variants have been reported to cause a younger adult-onset NCL. Initially described in two siblings, the age at onset was in their early 20s with progressive vision loss and seizures, followed by ataxia, cognitive decline, and retinal dystrophy. A subsequent case series has expanded the phenotype to include age at onset as young as seven years [<a href="#rid34">34,94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN12 disease</strong> – CLN12 disease is better known as Kufor-Rakeb syndrome (or PARK9). It was initially described in a consanguineous Jordanian family [<a href="#rid95">95</a>]. The clinical features include the parkinsonian features of masklike face, rigidity, and bradykinesia but without tremor. Spasticity, supranuclear upgaze paresis, and dementia are present in most affected individuals [<a href="#rid96">96</a>]. Age at onset is in early adolescence; symptoms progress rapidly. Kufor-Rakeb syndrome is caused by loss-of-function pathogenic variants in a predominantly neuronal P-type ATPase gene, <em>ATP13A2 </em>[<a href="#rid97">97,98</a>]. Description of typical NCL pathology in a family with pathogenic variants in <em>ATP13A2</em> led to the alternative classification as CLN12 disease [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN13 disease</strong> – CLN13 disease is due to pathogenic variants in the <em>CTSF</em> gene that codes for cathepsin F. Pathogenic variants in <em>CTSF</em> appear to account for the majority of cases of adult-onset NCL of the type B Kufs phenotype [<a href="#rid80">80,100</a>]. Type B Kufs is characterized by dementia with cerebellar and/or extrapyramidal motor symptoms. Onset is typically in early adulthood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CLN14 disease</strong> – CLN14 disease is due to pathogenic variants in the <em>KCTD7</em> gene that codes for the potassium channel tetramerization domain-containing protein 7 [<a href="#rid101">101</a>]. It is characterized by rapidly progressive neurodegeneration with onset of intractable myoclonic seizures before age 2 years accompanied by developmental regression. This condition has also been classified as a progressive myoclonic epilepsy (EPM3) [<a href="#rid102">102</a>], but, as intracellular accumulation of autofluorescent lipopigment storage material has been identified in some affected individuals [<a href="#rid101">101</a>], it has been designated as CLN14. Ultrastructural findings on skin biopsies are variable, but the clinical features are generally consistent across reports.</p><p></p><p class="headingAnchor" id="H4135955126"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>For the child presenting with developmental regression or concern for neurodegenerative disease, efficiently achieving an accurate, early diagnosis, if possible, is important for guiding treatment decision making, anticipatory guidance, family planning, bringing to a close the diagnostic odyssey, connecting to disease-specific support groups, and determining eligibility for clinical trials [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H1715305715"><span class="h2">When to suspect NCL</span><span class="headingEndMark"> — </span>There are several clusters of signs and symptoms that suggest an NCL diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Developmental regression affecting infants and children</p><p class="bulletIndent1"><span class="glyph">●</span>Refractory epilepsy plus neurologic symptoms at any age</p><p class="bulletIndent1"><span class="glyph">●</span>Vision loss (especially retinopathy) plus neurologic symptoms at any age</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive ataxia with cerebellar atrophy at any age</p><p></p><p>NCLs are one of the most prevalent causes of pediatric dementia [<a href="#rid104">104,105</a>] (see  <a class="medical medical_review" href="/d/html/6189.html" rel="external">"Intellectual disability in children: Evaluation for a cause"</a>). In a study of 300 individuals with childhood-onset ataxia with cerebellar atrophy, 18 percent had an NCL diagnosis [<a href="#rid106">106</a>].</p><p>It is important to include CLN2 disease in the growing list of treatable neurologic disorders of childhood, making ascertainment of an NCL diagnosis, when present, critically important.</p><p>Some children with NCL are first diagnosed with autism spectrum disorder, and some children with an NCL diagnosis have hand stereotypies reminiscent of Rett syndrome or FOXG1 disorders [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H103552089"><span class="h2">Brain imaging</span><span class="headingEndMark"> — </span>When infants or children present with global developmental delay or developmental regression, we suggest early brain imaging, especially in the setting of seizures, abnormal neurologic examination findings, and/or macrocephaly or microcephaly [<a href="#rid108">108-111</a>]. Brain magnetic resonance imaging (MRI) is likely to have greater diagnostic yield compared with head computed tomography (CT) in this context and has the added benefit of avoiding radiation exposure. While imaging alone is nonspecific and is insufficient for establishing an NCL diagnosis, it may provide important clues that suggest a neurodegenerative condition is present, especially when cerebral and cerebellar atrophy are observed, which has been reported in most NCLs [<a href="#rid17">17,112</a>].</p><p>Of note, while diffuse cerebellar atrophy is an eventual universal finding in infantile-onset CLN1 disease [<a href="#rid19">19,112,113</a>], conventional brain MRI may be normal in children with CLN3 disease younger than age 10 years; cerebral atrophy becomes evident in adolescence followed by cerebellar atrophy [<a href="#rid114">114</a>]. Thalamic T2 hypointensity has been reported in several NCLs including CLN1, CLN2, CLN3, CLN5, and CLN7; this finding may also be observed in other neuronal lysosomal diseases [<a href="#rid19">19,113,115</a>].</p><p>The NCLs are primarily considered grey matter disorders, but white matter abnormalities have been described in CLN2 [<a href="#rid116">116</a>] and CLN3 [<a href="#rid117">117</a>].</p><p class="headingAnchor" id="H2351363792"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is the primary path to diagnosis for most individuals. When there is high suspicion for a specific NCL (eg, concern for CLN3 disease in a child with rapidly progressive vision loss and mild cognitive impairment at five years of age), single gene sequencing and deletion/duplication analysis may be appropriate.</p><p>In most cases, the clinical suspicion is more likely to be for NCLs as a group, a genetic form of epilepsy, or for a neurodegenerative disorder broadly. In these cases, it may be more appropriate to pursue panel-based, next-generation sequencing with deletion/duplication analysis for NCLs using NCL gene panels, epilepsy gene panels, or lysosomal disease gene panels, depending on the level of diagnostic certainty [<a href="#rid118">118</a>]. A broad-based approach to diagnosis is often needed due to overlapping symptom presentations.</p><p>Whole exome sequencing is increasingly used as a tool in the diagnostic evaluation of children with complex neurologic conditions. This approach may also yield a specific NCL diagnosis. However, some limitations apply. Large deletions and duplications may be missed by this approach, evaluation of variants of unknown significance may be challenging (given the rarity of these disorders), and confirmatory testing with enzyme analysis (for CLN1 and CLN2 disease) or tissue biopsy (to evaluate for lysosomal storage) may be required for diagnosis in certain cases.</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ucl.ac.uk%2Fncl-disease%2Fmutation-and-patient-database&amp;token=Mbamg%2FCxnjOwXb7Mzfd1qITcm956qY0X6Xv6pzGGejC7BwJJsM5bHQsFCD8ScLngEWzMW4Yn4t3q1GcESHmM068AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=126618" target="_blank">NCL Mutation and Patient Database</a> is an additional resource for clarifying the nature of variants of unknown significance. In cases where the suspicion for an NCL disorder is very high and only a single pathogenic variant is found in an NCL gene, intronic pathogenic variants may also be explored in conjunction with an experienced geneticist [<a href="#rid119">119</a>]. There are also isolated case reports of NCLs due to uniparental disomy [<a href="#rid120">120</a>]. In the setting of a sibling with known genetic diagnosis, testing may begin with targeted analysis for the same pathogenic variant. Where insurance coverage and cost represent barriers to testing, there are an increasing number of industry-sponsored comprehensive epilepsy and lysosomal disease next-generation sequencing panels available at no financial cost to the patient.</p><p class="headingAnchor" id="H1404650034"><span class="h2">Other studies</span><span class="headingEndMark"> — </span>Enzyme testing, once a first-line diagnostic test for CLN1 and CLN2 disease, increasingly represents a secondary line of diagnostic or confirmatory testing. Similarly, tissue biopsy with electron microscopic analysis was once considered first-line in the diagnostic approach for all NCLs, but it, too, now represents a means of confirming or excluding an NCL diagnosis when genetic testing results are uncertain or inconclusive. Tissue sampling from the skin is most common; conjunctiva and rectal tissues constitute additional sources [<a href="#rid18">18</a>].</p><p>As in other complex neurodegenerative disorders, a thorough ophthalmologic examination may be beneficial, even in the absence of known vision loss. Evidence of early retinopathy in the setting of developmental regression may point to NCLs as a class of disorders. Electroretinography may be helpful to further assess retinal involvement in some settings.</p><p>While epilepsy is a common feature in NCLs, electroencephalography findings are generally nonspecific. It has been suggested that photosensitivity to low-frequency photic stimulation (1 to 5 Hz) may be a hallmark of NCL disorders, but this has not been studied extensively across NCLs [<a href="#rid17">17,121,122</a>].</p><p class="headingAnchor" id="H1582019060"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for dementias of childhood is broad and includes genetic, metabolic, and inflammatory etiologies. Other neuronal lysosomal diseases, leukoencephalopathies, mitochondrial diseases, and peroxisomal disorders should be considered in children presenting with developmental regression with or without epilepsy.</p><p>The British Paediatric Surveillance Unit launched the progressive intellectual and neurologic deterioration study in 1997, tracking occurrence and diagnosis of neurodegenerative conditions of childhood [<a href="#rid104">104,105</a>]. In the 2019 analysis from this ongoing study, the most common diagnoses in a cohort of 1819 children with symptoms and signs of neurodegeneration were late infantile NCL, mucopolysaccharidosis type III, metachromatic leukodystrophy, Rett syndrome, adrenoleukodystrophy, juvenile NCL, Krabbe disease, Tay-Sachs disease, Niemann Pick type C, and Sandhoff disease [<a href="#rid105">105</a>]. Many of these conditions are primarily white matter diseases and lack prominent epilepsy combined with retinal degeneration. More than 190 different diagnoses were found in the cohort, confirming that the differential diagnosis can be expansive.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenoleukodystrophy</strong> (ALD) is an X-linked peroxisomal disorder that results in accumulation of very long-chain fatty acids (VLCFAs) in all tissues. ALD consists of a spectrum of phenotypes (including childhood cerebral forms, adrenomyeloneuropathy, and primary adrenal insufficiency) that vary in the age and severity of clinical presentation. Female carriers often develop myelopathy and polyneuropathy during adulthood. (See  <a class="medical medical_review" href="/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Krabbe disease</strong> is an autosomal recessive disorder caused by the deficiency of galactocerebrosidase (GALC). The pathologic changes in the peripheral and central nervous system (globoid cell formation and decreased myelin) are hypothesized to result from the toxic nature of accumulated psychosine, which cannot be degraded because of the GALC deficiency. Most patients present with symptoms within the first six months of life; approximately 10 percent present later in life, including adulthood. A peripheral motor sensory neuropathy occurs in all patients, but the early-onset forms are dominated by symptoms related to central nervous system dysfunction. Infantile onset disease is associated with irritability, developmental delay or regression, limb spasticity, axial hypotonia, absent reflexes, optic atrophy, and microcephaly. Seizures and tonic extensor spasms eventually appear. Typically there is rapid regression to a decerebrate condition and death in most cases before two years of age. (See  <a class="medical medical_review" href="/d/html/6188.html" rel="external">"Krabbe disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metachromatic leukodystrophy</strong> (MLD) is an autosomal recessive lysosomal disease caused by pathogenic variants in the arylsulfatase A gene (<em>ARSA</em>). In a few patients, a variant form of MLD is caused by pathogenic variants in the prosaposin gene (<em>PSAP</em>). The late infantile form of MLD presents from age six months to two years; early signs include regression of motor skills, gait difficulty, ataxia, hypotonia, extensor plantar responses, optic atrophy, and peripheral neuropathy. The juvenile form of MLD presents between 3 and 16 years of age with gait disturbance, intellectual impairment, ataxia, upper motor neuron signs, and a peripheral neuropathy. Seizures may occur. Adult onset MLD (age 17 or older) is usually heralded by dementia and behavioral difficulties. (See  <a class="medical medical_review" href="/d/html/6195.html" rel="external">"Metachromatic leukodystrophy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The mucopolysaccharidoses</strong> (MPS) are lysosomal diseases caused by the deficiency of enzymes required for the stepwise breakdown of glycosaminoglycans (GAGs). Fragments of partially degraded GAGs accumulate in the lysosomes, resulting in cellular dysfunction and clinical abnormalities. MPS type III (Sanfilippo syndrome) is caused by a deficiency of one of four enzymes involved in the degradation of heparan sulfate, leading to its accumulation. All forms have autosomal recessive inheritance. An MPS disorder should be suspected in a child with coarse facial features, hepatosplenomegaly, and bone disease (dysostosis multiplex), with or without central nervous system (CNS) abnormalities. MPS type III is characterized primarily by progressive CNS degeneration. Hepatosplenomegaly, while characteristic of MPS disorders, is not observed in NCL conditions. (See  <a class="medical medical_review" href="/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Niemann-Pick disease type C</strong> (NPD-C) is caused by pathogenic variants of the <em>NPC1</em> and <em>NPC2</em> genes that result in impaired cellular processing and transport of low-density lipoprotein (LDL) cholesterol. NPD-C can present from the perinatal period until late adulthood. Most patients with NPD-C have disease onset in middle to late childhood, typically with cerebellar symptoms, slow cognitive deterioration, vertical supranuclear gaze palsy, and progressive dystonia, dysarthria, and dysphagia. (See  <a class="medical medical_review" href="/d/html/6196.html" rel="external">"Overview of Niemann-Pick disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rett syndrome</strong> (RTT) is a rare neurodevelopmental disorder that occurs almost exclusively in females. In the majority of patients with typical or atypical RTT, the disorder is caused by pathogenic variants in the <em>MECP2</em> gene. A minority of patients have atypical RTT caused by pathogenic variants in <em>CDKL5 </em>or <em>FOXG1</em> genes. With typical RTT, patients initially develop normally and then experience loss of speech and purposeful hand use and onset of stereotypic hand movement and gait abnormalities. Deceleration of head growth can be one of the first signs, beginning as early as two to three months of age. Additional manifestations can include seizures, autistic features, intermittent breathing abnormalities, autonomic nervous system dysfunction, cardiac abnormalities, and sleep disturbances. Atypical RTT encompasses variants of RTT that have many but not all of the clinical features of typical RTT. (See  <a class="medical medical_review" href="/d/html/6178.html" rel="external">"Rett syndrome: Genetics, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1277983011"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3040379730"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>In general, the principles of management for individuals with NCL disorders follow the principles of symptomatic management for developmental and neurologic conditions based on common practice.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic strategies</strong> – There are some pharmacologic strategies commonly used for management of neurologic sequelae of NCL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epilepsy</strong> – For patients with NCL and epilepsy, antiseizure medications that may be helpful include <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, and <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, recognizing that this is not a precise or exhaustive list, and that epilepsy in this setting is often resistant to treatment [<a href="#rid123">123</a>]. The mood stabilizing effect of valproate is a potential advantage for patients with juvenile NCL who may have psychotic symptoms. However, in one small series, valproate-induced hyperammonemic encephalopathy developed in 4 of 14 patients (29 percent) with juvenile NCL who were treated with valproate, suggesting an increased risk compared with other populations [<a href="#rid124">124</a>]. Agitation is a possible adverse effect of topiramate and levetiracetam. Topiramate may be started at a low dose (0.5 mg/kg per day) in patients with NCL and titrated slowly to minimize other adverse effects, which include cognitive impairment and language disturbance [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a> and  <a class="medical medical_review" href="/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a> and  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Spasticity</strong> – For patients with NCL, our preferred treatment option for spasticity is <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a>, although high doses are often required [<a href="#rid123">123</a>]. Benzodiazepines are an alternative, and may be preferred as a first choice for patients with dyskinesia. <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">Tizanidine</a> is also an option. Botulinum toxin injections can be helpful for relieving focal or segmental spasticity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Movement disorders</strong> – Treatment of movement disorders in the NCLs may be difficult due to the complexity of movement disorder combinations and often treatment-refractory symptoms. Movement disorders that do not affect patient function, safety, or comfort need not be treated. For debilitating myoclonus, potentially useful treatments include benzodiazepines, <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>, and piracetam [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2">One report described two sisters with CLN3 disease who developed dystonic storm (ie, status dystonicus, a life-threatening condition characterized by acute worsening of dystonia and complicated by bulbar weakness, progressive impairment of respiratory function, and metabolic derangements including rhabdomyolysis and acute kidney injury); abnormal movements improved after one sister was treated with bilateral pallidotomy and the other with bilateral pallidotomy followed by deep brain stimulation [<a href="#rid125">125</a>]. (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Status dystonicus'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mood and behavior disorders</strong> – Caution should be used when considering dopamine D2 receptor antagonists for treatment of mood and behavior in CLN3 disease due to risk for inducing or worsening the parkinsonism associated with the disease. <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a> may be a better choice due to low D2 receptor affinity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cognitive regression</strong> – There are no direct pharmacologic strategies for management of cognitive regression, though therapeutic supports for management of mood and behavior can be essential.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac disorders</strong> – As supportive care improves and life expectancy lengthens in NCLs, a cardiac phenotype in these disorders is increasingly recognized. Providers should be aware of cardiac conduction abnormalities observed with increasing age in CLN1, CLN2, and CLN3 diseases [<a href="#rid63">63,126,127</a>] and cases of cardiomyopathy [<a href="#rid126">126,128</a>]. In the author's clinical experience, some practitioners and families opt for pacemaker placement when symptomatic cardiac arrhythmias reduce the quality of life.</p><p></p><p class="bulletIndent1">A number of agents have shown <strong>no</strong> definite evidence of therapeutic benefit in patients with NCL, including <a class="drug drug_general" data-topicid="9313" href="/d/drug information/9313.html" rel="external">cysteamine</a> and <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (CLN1 disease) [<a href="#rid129">129</a>], <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (CLN3 disease) [<a href="#rid130">130</a>], flupirtine (CLN3 disease) [<a href="#rid131">131</a>], melatonin (CLN3 disease) [<a href="#rid132">132</a>], antioxidants (CLN3 disease) [<a href="#rid133">133</a>], antiparkinsonian medications (CLN3 disease) [<a href="#rid134">134</a>], central nervous system stem cell transplantation (CLN1 and CLN2 disease) [<a href="#rid135">135</a>], and intermittent <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> (CLN3 disease) [<a href="#rid136">136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpharmacologic interventions</strong> – Nonpharmacologic interventions for patients with NCL are a critical aspect of disease management, including prevention of complications. These interventions may include physical, occupational, vision, and speech therapies; use of adaptive devices; nutritional supports; diet modification; good sleep hygiene; family and caregiver support; and palliative care integration starting early in the disease course [<a href="#rid103">103,137</a>].</p><p></p><p class="headingAnchor" id="H1829236062"><span class="h2">Disease-modifying therapy for CLN2</span><span class="headingEndMark"> — </span>For patients with symptomatic CLN2 disease who are age 3 years and older, we recommend treatment with <a class="drug drug_general" data-topicid="112989" href="/d/drug information/112989.html" rel="external">recombinant human cerliponase alfa</a> [<a href="#rid138">138</a>]. This drug is a proenzyme form of human TPP1, which is deficient in patients with CLN2 disease. It administered into the cerebrospinal fluid via the lateral ventricles. It represents the first disease-modifying therapy for any NCL.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indication</strong> – <a class="drug drug_general" data-topicid="112989" href="/d/drug information/112989.html" rel="external">Recombinant human cerliponase alfa</a> was approved to slow the loss of ambulation in children age 3 years and older with symptomatic CLN2 disease [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy of <a class="drug drug_general" data-topicid="112989" href="/d/drug information/112989.html" rel="external">recombinant human cerliponase alfa</a> was established in an open-label study of 23 children ages 3 to 16 years with CLN2 disease who were treated with intraventricular infusion of cerliponase alfa for at least 96 weeks and a historical control group of 42 patients with CLN2 disease [<a href="#rid140">140</a>]. Outcome was measured using the motor and language domains of the Hamburg CLN2 Clinical Rating Scale, where 0 represents no function and 3 represents normal function in each of the two domains, and aggregate scores range from 0 to 6.</p><p></p><p class="bulletIndent1">Compared with historical controls, treated patients were less likely to decline in motor and language function, as measured by the median time until a 2-point decline in the combined motor-language score, a lower risk of an unreversed two-point decline in the combined motor-language score (hazard ratio 0.08; 95% CI 0.02-0.23), and a lower unadjusted mean rate of decline per 48-week period in the combined motor-language score (-0.27 for treated patients, compared with -2.12 for controls) [<a href="#rid140">140</a>]. An extension study with more than five years of follow-up found that treated patients continued to have slower decline of motor and language function compared with historical controls, with a lower risk of an unreversed 2-point decline or a score of 0 in the combined motor-language score (hazard ratio 0.14; 95% CI 0.06-0.33) [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Pretreatment with antihistamines with or without antipyretics or glucocorticoids is given 30 to 60 minutes prior to start of the infusion [<a href="#rid142">142</a>]. Cerliponase alfa 300 mg (10 mL) is given once every other week (followed by intraventricular electrolytes 2 mL, included in the administration kit) and infused at a rate of 2.5 mL per hour via a surgically implanted intracranial ventricular reservoir and infusion device. The first dose may be given five to seven days after device implantation. Aseptic technique must be strictly followed during preparation and administration [<a href="#rid143">143</a>]. Treatment should be managed by clinicians with expertise in intraventricular administration [<a href="#rid144">144</a>]. Since there is a risk of anaphylaxis, the drug should be given in a setting with appropriate facilities and medical support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse clinical effects with cerliponase alfa are pyrexia, electrocardiogram (ECG) abnormalities, vomiting, seizures, hypersensitivity, hematoma, headache, irritability, device-related infections, bradycardia, jittery feeling, and hypotension [<a href="#rid141">141-143</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Replacement of the intraventricular access device is recommended prior to four years of use [<a href="#rid142">142</a>]. In longitudinal studies, breakdown of implanted intracranial ventricular reservoirs has been observed after 105 perforations, the number that would accrue over approximately four years of cerliponase alfa administration.</p><p></p><p class="headingAnchor" id="H2303180183"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The neuronal ceroid lipofuscinoses (NCL) are a group of lysosomal diseases characterized by progressive neurodegeneration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The NCLs were originally grouped into four classic forms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infantile NCL (Haltia-Santavuori disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Late infantile NCL (Janský-Bielschowsky disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Juvenile NCL (Batten-Spielmeyer-Vogt disease, or simply Batten disease)</p><p class="bulletIndent2"><span class="glyph">•</span>Adult NCL (Kufs disease)</p><p></p><p class="bulletIndent1">Over time, investigators have described additional forms of NCL with clinical features similar to those of the classic forms. NCL experts now recommend primary disease classification by gene or protein (eg, CLN1 disease or PPT1 deficiency) and secondary classification by age at onset and clinical features. (See <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal intracellular storage materials accumulate in all NCL disorders, comprised of a mixture of lipids and proteins, morphologically characterized as ceroid lipofuscin. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least 13 different genetic forms of NCL have been identified. Collectively, NCLs are the most prevalent neurodegenerative disorders of childhood [<a href="#rid11">11</a>]. However, the individual NCLs are rare conditions. (See <a class="local">'Genetics'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Though unified by common features of vision loss, dementia, movement disorders, and epilepsy, the neuronal ceroid lipofuscinoses (NCLs) represent a group of distinct conditions manifesting genetic heterogeneity and phenotypic pleiotropy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When infants or children present with global developmental delay or developmental regression, we suggest early brain imaging, especially in the setting of seizures, abnormal neurologic examination findings, and/or macrocephaly or microcephaly. Genetic testing is the primary path to diagnosis of NCL for most individuals. A broad-based approach is often needed and may include NCL gene panels, epilepsy gene panels, lysosomal disease gene panels, or whole exome sequencing. Enzymatic testing (for CLN1 or CLN2 disease) and/or skin biopsy to evaluate for lysosomal inclusions may serve as confirmatory strategies in the setting of inconclusive genetic testing, or when genetic testing is unavailable. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to management is supportive for most NCLs. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with CLN2 disease who are age 3 years and older, we recommend treatment with <a class="drug drug_general" data-topicid="112989" href="/d/drug information/112989.html" rel="external">recombinant human cerliponase alfa</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Disease-modifying therapy for CLN2'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stengel OC. Beretning om et maerkeligt Sygdomstilfaelde hos fire Sødskende i Nærheden af Röraas. Eyr 1826; 1:347.</a></li><li><a class="nounderline abstract_t">Batten FE. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Trans Ophthalmol Soc UK 1903; 23:386.</a></li><li><a class="nounderline abstract_t">Spielmeyer W. Über familiäre amaurotische Idiotien. Neurol Cbl 1905; 24:620.</a></li><li><a class="nounderline abstract_t">Vogt H. Über familiäre amaurotische Idiotie und verwandte Krankheitsbilder. Mschr Psychiatr Neurol 1905; 18:161.</a></li><li><a class="nounderline abstract_t">Janský J. Dosud nepopsaný pripad familiárni amaurotické idiotie komplikované s hypoplasii mozeckovou. Sborn Lék 1908; 13:165.</a></li><li><a class="nounderline abstract_t">Bielschowsky M. Über spätinfantile familiäre amaurotische Idiotie mit Kleinhirnsymptonen. Deutsche Zeitschrift für Nervenheilkunde 1913; 50:7.</a></li><li><a class="nounderline abstract_t">Kufs H. Über eine Spätform der amaurotischen Idiotie und ihre heredofamiliären Grundlagen. Z Ges Neurol Psychiatr 1925; 95:169.</a></li><li><a class="nounderline abstract_t">Haltia M, Rapola J, Santavuori P, Keränen A. Infantile type of so-called neuronal ceroid-lipofuscinosis. 2. Morphological and biochemical studies. J Neurol Sci 1973; 18:269.</a></li><li><a class="nounderline abstract_t">Santavuori P, Haltia M, Rapola J, Raitta C. Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients. J Neurol Sci 1973; 18:257.</a></li><li><a class="nounderline abstract_t">Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 2003; 62:1.</a></li><li class="breakAll">Williams RE, Goebel HH, Mole SE. NCL nomenclature and classification. In: The Neuronal Ceroid Lipofuscinoses (Batten Disease), 2nd ed, Mole SE, Williams RE, Goebel HH (Eds), Oxford University Press, Oxford 2011. p.20.</li><li><a class="nounderline abstract_t">Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 2012; 79:183.</a></li><li><a class="nounderline abstract_t">Götzl JK, Mori K, Damme M, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 2014; 127:845.</a></li><li><a class="nounderline abstract_t">Parviainen L, Dihanich S, Anderson GW, et al. Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons. Acta Neuropathol Commun 2017; 5:74.</a></li><li><a class="nounderline abstract_t">Xiong J, Kielian T. Microglia in juvenile neuronal ceroid lipofuscinosis are primed toward a pro-inflammatory phenotype. J Neurochem 2013; 127:245.</a></li><li><a class="nounderline abstract_t">Nelvagal HR, Lange J, Takahashi K, et al. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis 2020; 1866:165570.</a></li><li><a class="nounderline abstract_t">Berkovic SF, Oliver KL, Canafoglia L, et al. Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features. Brain 2019; 142:59.</a></li><li><a class="nounderline abstract_t">Aungaroon G, Hallinan B, Jain P, et al. Correlation Among Genotype, Phenotype, and Histology in Neuronal Ceroid Lipofuscinoses: An Individual Patient Data Meta-Analysis. Pediatr Neurol 2016; 60:42.</a></li><li><a class="nounderline abstract_t">Jadav RH, Sinha S, Yasha TC, et al. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol 2014; 50:85.</a></li><li><a class="nounderline abstract_t">Danyukova T, Ariunbat K, Thelen M, et al. Loss of CLN7 results in depletion of soluble lysosomal proteins and impaired mTOR reactivation. Hum Mol Genet 2018; 27:1711.</a></li><li><a class="nounderline abstract_t">Getty AL, Pearce DA. Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell Mol Life Sci 2011; 68:453.</a></li><li><a class="nounderline abstract_t">Vesa J, Chin MH, Oelgeschläger K, et al. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. Mol Biol Cell 2002; 13:2410.</a></li><li><a class="nounderline abstract_t">Cárcel-Trullols J, Kovács AD, Pearce DA. Role of the Lysosomal Membrane Protein, CLN3, in the Regulation of Cathepsin D Activity. J Cell Biochem 2017; 118:3883.</a></li><li><a class="nounderline abstract_t">Stekhoven JH, van Haelst UJ, Joosten EM, Loonen MC. Ultrastructural study of the vacuoles in the peripheral lymphocytes in juvenile amaurotic idiocy. Juvenile form of generalized ceroid lipofuscinosis. Acta Neuropathol 1977; 38:137.</a></li><li><a class="nounderline abstract_t">Medoh UN, Hims A, Chen JY, et al. The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase. Science 2023; 381:1182.</a></li><li><a class="nounderline abstract_t">Cárcel-Trullols J, Kovács AD, Pearce DA. Cell biology of the NCL proteins: What they do and don't do. Biochim Biophys Acta 2015; 1852:2242.</a></li><li><a class="nounderline abstract_t">Mukherjee AB, Appu AP, Sadhukhan T, et al. Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. Mol Neurodegener 2019; 14:4.</a></li><li><a class="nounderline abstract_t">Holopainen JM, Saarikoski J, Kinnunen PK, Järvelä I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem 2001; 268:5851.</a></li><li><a class="nounderline abstract_t">Kyttälä A, Lahtinen U, Braulke T, Hofmann SL. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim Biophys Acta 2006; 1762:920.</a></li><li><a class="nounderline abstract_t">Mamo A, Jules F, Dumaresq-Doiron K, et al. The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting. Mol Cell Biol 2012; 32:1855.</a></li><li><a class="nounderline abstract_t">Stoka V, Turk V, Turk B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res Rev 2016; 32:22.</a></li><li><a class="nounderline abstract_t">Rusyn E, Mousallem T, Persaud-Sawin DA, et al. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr Res 2008; 63:625.</a></li><li><a class="nounderline abstract_t">Berkovic SF, Carpenter S, Andermann F, et al. Kufs' disease: a critical reappraisal. Brain 1988; 111 ( Pt 1):27.</a></li><li><a class="nounderline abstract_t">Smith KR, Damiano J, Franceschetti S, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 2012; 90:1102.</a></li><li><a class="nounderline abstract_t">Cardona F, Rosati E. Neuronal ceroid-lipofuscinoses in Italy: an epidemiological study. Am J Med Genet 1995; 57:142.</a></li><li><a class="nounderline abstract_t">Santorelli FM, Garavaglia B, Cardona F, et al. Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy. Orphanet J Rare Dis 2013; 8:19.</a></li><li><a class="nounderline abstract_t">Sleat DE, Gedvilaite E, Zhang Y, et al. Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis. Gene 2016; 593:284.</a></li><li class="breakAll">The Neuronal Ceroid Lipofuscinoses (Batten Disease), 2nd ed, Mole SE, Williams RE, Goebel HH (Eds), Oxford University Press, Oxford 2011.</li><li><a class="nounderline abstract_t">Kohan R, Pesaola F, Guelbert N, et al. The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina. Biochim Biophys Acta 2015; 1852:2301.</a></li><li><a class="nounderline abstract_t">Mink JW, Augustine EF, Adams HR, et al. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol 2013; 28:1101.</a></li><li><a class="nounderline abstract_t">Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995; 376:584.</a></li><li><a class="nounderline abstract_t">Santavuori P, Haltia M, Rapola J. Infantile type of so-called neuronal ceroid-lipofuscinosis. Dev Med Child Neurol 1974; 16:644.</a></li><li><a class="nounderline abstract_t">Becker K, Goebel HH, Svennerholm L, et al. Clinical, morphological, and biochemical investigations on a patient with an unusual form of neuronal ceroid-lipofuscinosis. Eur J Pediatr 1979; 132:197.</a></li><li><a class="nounderline abstract_t">Das AK, Becerra CH, Yi W, et al. Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S. J Clin Invest 1998; 102:361.</a></li><li><a class="nounderline abstract_t">Wisniewski KE, Connell F, Kaczmarski W, et al. Palmitoyl-protein thioesterase deficiency in a novel granular variant of LINCL. Pediatr Neurol 1998; 18:119.</a></li><li><a class="nounderline abstract_t">Ramadan H, Al-Din AS, Ismail A, et al. Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1. Neurology 2007; 68:387.</a></li><li><a class="nounderline abstract_t">van Diggelen OP, Thobois S, Tilikete C, et al. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann Neurol 2001; 50:269.</a></li><li><a class="nounderline abstract_t">Das AK, Lu JY, Hofmann SL. Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis. Hum Mol Genet 2001; 10:1431.</a></li><li><a class="nounderline abstract_t">Golabek AA, Walus M, Wisniewski KE, Kida E. Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo. J Biol Chem 2005; 280:7550.</a></li><li><a class="nounderline abstract_t">Steinfeld R, Heim P, von Gregory H, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 2002; 112:347.</a></li><li><a class="nounderline abstract_t">Nickel M, Simonati A, Jacoby D, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018; 2:582.</a></li><li class="breakAll">Pediatric Neuro-Ophthalmology, Brodsky MC, Baker RS, Hamed LS (Eds), Springer-Verlag, New York 1996.</li><li><a class="nounderline abstract_t">Kohan R, Carabelos MN, Xin W, et al. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America. Gene 2013; 516:114.</a></li><li><a class="nounderline abstract_t">Taratuto AL, Saccoliti M, Sevlever G, et al. Childhood neuronal ceroid-lipofuscinoses in Argentina. Am J Med Genet 1995; 57:144.</a></li><li><a class="nounderline abstract_t">Dy ME, Sims KB, Friedman J. TPP1 deficiency: Rare cause of isolated childhood-onset progressive ataxia. Neurology 2015; 85:1259.</a></li><li><a class="nounderline abstract_t">Sun Y, Almomani R, Breedveld GJ, et al. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease). Hum Mutat 2013; 34:706.</a></li><li><a class="nounderline abstract_t">Adams HR, Beck CA, Levy E, et al. Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Dev Med Child Neurol 2010; 52:637.</a></li><li><a class="nounderline abstract_t">Kwon JM, Adams H, Rothberg PG, et al. Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 2011; 77:1801.</a></li><li><a class="nounderline abstract_t">Cialone J, Adams H, Augustine EF, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis 2012; 35:549.</a></li><li><a class="nounderline abstract_t">Marshall FJ, de Blieck EA, Mink JW, et al. A clinical rating scale for Batten disease: reliable and relevant for clinical trials. Neurology 2005; 65:275.</a></li><li><a class="nounderline abstract_t">Kuper WFE, van Alfen C, Rigterink RH, et al. Timing of cognitive decline in CLN3 disease. J Inherit Metab Dis 2018; 41:257.</a></li><li><a class="nounderline abstract_t">Nielsen AK, Østergaard JR. Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience. Eur J Paediatr Neurol 2013; 17:265.</a></li><li><a class="nounderline abstract_t">Ostergaard JR, Rasmussen TB, Mølgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 2011; 76:1245.</a></li><li><a class="nounderline abstract_t">Rietdorf K, Coode EE, Schulz A, et al. Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity. Biochim Biophys Acta Mol Basis Dis 2020; 1866:165643.</a></li><li><a class="nounderline abstract_t">Cameron JM, Damiano JA, Grinton B, et al. Recognition and epileptology of protracted CLN3 disease. Epilepsia 2023; 64:1833.</a></li><li><a class="nounderline abstract_t">Sarpong A, Schottmann G, Rüther K, et al. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X). Clin Genet 2009; 76:38.</a></li><li><a class="nounderline abstract_t">Ku CA, Hull S, Arno G, et al. Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration. JAMA Ophthalmol 2017; 135:749.</a></li><li><a class="nounderline abstract_t">Cortese A, Tucci A, Piccolo G, et al. Novel CLN3 mutation causing autophagic vacuolar myopathy. Neurology 2014; 82:2072.</a></li><li><a class="nounderline abstract_t">Nosková L, Stránecký V, Hartmannová H, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet 2011; 89:241.</a></li><li><a class="nounderline abstract_t">Velinov M, Dolzhanskaya N, Gonzalez M, et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. PLoS One 2012; 7:e29729.</a></li><li><a class="nounderline abstract_t">Boehme DH, Cottrell JC, Leonberg SC, Zeman W. A dominant form of neuronal ceroid-lipofuscinosis. Brain 1971; 94:745.</a></li><li><a class="nounderline abstract_t">Santavuori P, Rapola J, Sainio K, Raitta C. A variant of Jansky-Bielschowsky disease. Neuropediatrics 1982; 13:135.</a></li><li><a class="nounderline abstract_t">Xin W, Mullen TE, Kiely R, et al. CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL. Neurology 2010; 74:565.</a></li><li><a class="nounderline abstract_t">Simonati A, Williams RE, Nardocci N, et al. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev Med Child Neurol 2017; 59:815.</a></li><li><a class="nounderline abstract_t">Mancini C, Nassani S, Guo Y, et al. Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations. J Neurol 2015; 262:173.</a></li><li><a class="nounderline abstract_t">Gao H, Boustany RM, Espinola JA, et al. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 2002; 70:324.</a></li><li><a class="nounderline abstract_t">Arsov T, Smith KR, Damiano J, et al. Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am J Hum Genet 2011; 88:566.</a></li><li><a class="nounderline abstract_t">Chin JJ, Behnam B, Davids M, et al. Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients. Mol Genet Metab 2019; 126:188.</a></li><li><a class="nounderline abstract_t">Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 2005; 6:107.</a></li><li><a class="nounderline abstract_t">Smith KR, Dahl HH, Canafoglia L, et al. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet 2013; 22:1417.</a></li><li><a class="nounderline abstract_t">Topçu M, Tan H, Yalnizoğlu D, et al. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Turk J Pediatr 2004; 46:1.</a></li><li><a class="nounderline abstract_t">Kousi M, Siintola E, Dvorakova L, et al. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain 2009; 132:810.</a></li><li><a class="nounderline abstract_t">Khan KN, El-Asrag ME, Ku CA, et al. Specific Alleles of CLN7/MFSD8, a Protein That Localizes to Photoreceptor Synaptic Terminals, Cause a Spectrum of Nonsyndromic Retinal Dystrophy. Invest Ophthalmol Vis Sci 2017; 58:2906.</a></li><li><a class="nounderline abstract_t">Badura-Stronka M, Winczewska-Wiktor A, Pietrzak A, et al. CLN8 Mutations Presenting with a Phenotypic Continuum of Neuronal Ceroid Lipofuscinosis-Literature Review and Case Report. Genes (Basel) 2021; 12.</a></li><li><a class="nounderline abstract_t">Mitchell WA, Wheeler RB, Sharp JD, et al. Turkish variant late infantile neuronal ceroid lipofuscinosis (CLN7) may be allelic to CLN8. Eur J Paediatr Neurol 2001; 5 Suppl A:21.</a></li><li><a class="nounderline abstract_t">Allen NM, O'hIci B, Anderson G, et al. Variant late-infantile neuronal ceroid lipofuscinosis due to a novel heterozygous CLN8 mutation and de novo 8p23.3 deletion. Clin Genet 2012; 81:602.</a></li><li><a class="nounderline abstract_t">Cannelli N, Cassandrini D, Bertini E, et al. Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: Another genetic hit in the Mediterranean. Neurogenetics 2006; 7:111.</a></li><li><a class="nounderline abstract_t">Ranta S, Lehesjoki AE. Northern epilepsy, a new member of the NCL family. Neurol Sci 2000; 21:S43.</a></li><li><a class="nounderline abstract_t">Ranta S, Topcu M, Tegelberg S, et al. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat 2004; 23:300.</a></li><li><a class="nounderline abstract_t">Schulz A, Dhar S, Rylova S, et al. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol 2004; 56:342.</a></li><li><a class="nounderline abstract_t">Haddad SE, Khoury M, Daoud M, et al. CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches. Electrophoresis 2012; 33:3798.</a></li><li><a class="nounderline abstract_t">Steinfeld R, Reinhardt K, Schreiber K, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet 2006; 78:988.</a></li><li><a class="nounderline abstract_t">Hersheson J, Burke D, Clayton R, et al. Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 2014; 83:1873.</a></li><li><a class="nounderline abstract_t">Huin V, Barbier M, Bottani A, et al. Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. Brain 2020; 143:303.</a></li><li><a class="nounderline abstract_t">Najim al-Din AS, Wriekat A, Mubaidin A, et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994; 89:347.</a></li><li><a class="nounderline abstract_t">Williams DR, Hadeed A, al-Din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20:1264.</a></li><li><a class="nounderline abstract_t">Fong CY, Rolfs A, Schwarzbraun T, et al. Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation. Eur J Paediatr Neurol 2011; 15:271.</a></li><li><a class="nounderline abstract_t">Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38:1184.</a></li><li><a class="nounderline abstract_t">Bras J, Verloes A, Schneider SA, et al. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 2012; 21:2646.</a></li><li><a class="nounderline abstract_t">Di Fabio R, Moro F, Pestillo L, et al. Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease. Neurology 2014; 83:1769.</a></li><li><a class="nounderline abstract_t">Staropoli JF, Karaa A, Lim ET, et al. A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am J Hum Genet 2012; 91:202.</a></li><li><a class="nounderline abstract_t">Kousi M, Anttila V, Schulz A, et al. Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene. J Med Genet 2012; 49:391.</a></li><li><a class="nounderline abstract_t">Augustine EF, Adams HR, de Los Reyes E, et al. Management of CLN1 Disease: International Clinical Consensus. Pediatr Neurol 2021; 120:38.</a></li><li><a class="nounderline abstract_t">Verity C, Winstone AM, Stellitano L, et al. The epidemiology of progressive intellectual and neurological deterioration in childhood. Arch Dis Child 2010; 95:361.</a></li><li><a class="nounderline abstract_t">Verity C, Winstone AM, Will R, et al. Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies? Arch Dis Child 2019; 104:360.</a></li><li><a class="nounderline abstract_t">Al-Maawali A, Blaser S, Yoon G. Diagnostic approach to childhood-onset cerebellar atrophy: a 10-year retrospective study of 300 patients. J Child Neurol 2012; 27:1121.</a></li><li><a class="nounderline abstract_t">Craiu D, Dragostin O, Dica A, et al. Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature data on clinical onset signs. Eur J Paediatr Neurol 2015; 19:78.</a></li><li><a class="nounderline abstract_t">Moeschler JB, Shevell M, Committee on Genetics. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 2014; 134:e903.</a></li><li><a class="nounderline abstract_t">Bélanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability. Paediatr Child Health 2018; 23:403.</a></li><li><a class="nounderline abstract_t">Mithyantha R, Kneen R, McCann E, Gladstone M. Current evidence-based recommendations on investigating children with global developmental delay. Arch Dis Child 2017; 102:1071.</a></li><li><a class="nounderline abstract_t">Murias K, Moir A, Myers KA, et al. Systematic review of MRI findings in children with developmental delay or cognitive impairment. Brain Dev 2017; 39:644.</a></li><li><a class="nounderline abstract_t">Baker EH, Levin SW, Zhang Z, Mukherjee AB. MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis. AJNR Am J Neuroradiol 2017; 38:376.</a></li><li><a class="nounderline abstract_t">Vanhanen SL, Puranen J, Autti T, et al. Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease. Neuropediatrics 2004; 35:27.</a></li><li><a class="nounderline abstract_t">Autti T, Raininko R, Vanhanen SL, Santavuori P. MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology 1996; 38:476.</a></li><li><a class="nounderline abstract_t">Autti T, Joensuu R, Aberg L. Decreased T2 signal in the thalami may be a sign of lysosomal storage disease. Neuroradiology 2007; 49:571.</a></li><li><a class="nounderline abstract_t">Dyke JP, Sondhi D, Voss HU, et al. Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging. AJNR Am J Neuroradiol 2013; 34:884.</a></li><li><a class="nounderline abstract_t">Roine U, Roine TJ, Hakkarainen A, et al. Global and Widespread Local White Matter Abnormalities in Juvenile Neuronal Ceroid Lipofuscinosis. AJNR Am J Neuroradiol 2018; 39:1349.</a></li><li><a class="nounderline abstract_t">Fietz M, AlSayed M, Burke D, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab 2016; 119:160.</a></li><li><a class="nounderline abstract_t">Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med 2019; 381:1644.</a></li><li><a class="nounderline abstract_t">Niida Y, Yokoi A, Kuroda M, et al. A girl with infantile neuronal ceroid lipofuscinosis caused by novel PPT1 mutation and paternal uniparental isodisomy of chromosome 1. Brain Dev 2016; 38:674.</a></li><li><a class="nounderline abstract_t">Beltrán L, Valenzuela GR, Loos M, et al. Late-onset childhood neuronal ceroid lipofuscinosis: Early clinical and electroencephalographic markers. Epilepsy Res 2018; 144:49.</a></li><li><a class="nounderline abstract_t">Specchio N, Bellusci M, Pietrafusa N, et al. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia 2017; 58:1380.</a></li><li><a class="nounderline abstract_t">Schulz A, Kohlschütter A, Mink J, et al. NCL diseases - clinical perspectives. Biochim Biophys Acta 2013; 1832:1801.</a></li><li><a class="nounderline abstract_t">Larsen EP, Ostergaard JR. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). Seizure 2014; 23:429.</a></li><li><a class="nounderline abstract_t">Elkay M, Silver K, Penn RD, Dalvi A. Dystonic storm due to Batten's disease treated with pallidotomy and deep brain stimulation. Mov Disord 2009; 24:1048.</a></li><li><a class="nounderline abstract_t">Hofman IL, van der Wal AC, Dingemans KP, Becker AE. Cardiac pathology in neuronal ceroid lipofuscinoses--a clinicopathologic correlation in three patients. Eur J Paediatr Neurol 2001; 5 Suppl A:213.</a></li><li><a class="nounderline abstract_t">Fukumura S, Saito Y, Saito T, et al. Progressive conduction defects and cardiac death in late infantile neuronal ceroid lipofuscinosis. Dev Med Child Neurol 2012; 54:663.</a></li><li><a class="nounderline abstract_t">Khanji MY, Rusinova R, Shaukat M, Sekhri N. Neuronal ceroid lipofuscinosis with severe biventricular impairment: a rare genetic disorder with associated myopathy? Eur Heart J 2018; 39:74.</a></li><li><a class="nounderline abstract_t">Levin SW, Baker EH, Zein WM, et al. Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurol 2014; 13:777.</a></li><li><a class="nounderline abstract_t">Augustine EF, Beck CA, Adams HR, et al. Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis). JIMD Rep 2019; 43:117.</a></li><li><a class="nounderline abstract_t">Cialone J, Augustine EF, Newhouse N, et al. Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data. J Inherit Metab Dis 2011; 34:1075.</a></li><li><a class="nounderline abstract_t">Hätönen T, Kirveskari E, Heiskala H, et al. Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy. Mol Genet Metab 1999; 66:401.</a></li><li><a class="nounderline abstract_t">Santavuori P, Heiskala H, Autti T, et al. Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. Adv Exp Med Biol 1989; 266:273.</a></li><li><a class="nounderline abstract_t">Zweije-Hofman IL, van der Zee HJ, van Nieuwenhuizen O. Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial. Clin Neurol Neurosurg 1982; 84:101.</a></li><li><a class="nounderline abstract_t">Selden NR, Al-Uzri A, Huhn SL, et al. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr 2013; 11:643.</a></li><li><a class="nounderline abstract_t">Aberg L, Talling M, Härkönen T, et al. Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis. Neurology 2008; 70:1218.</a></li><li><a class="nounderline abstract_t">Mole SE, Schulz A, Badoe E, et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J Rare Dis 2021; 16:185.</a></li><li><a class="nounderline abstract_t">Lewis G, Morrill AM, Conway-Allen SL, Kim B. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2. J Child Neurol 2020; 35:348.</a></li><li class="breakAll">FDA approves first treatment for a form of Batten disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-batten-disease (Accessed on February 11, 2020).</li><li><a class="nounderline abstract_t">Schulz A, Ajayi T, Specchio N, et al. Study of Intraventricular Cerliponase Alfa for CLN2 Disease. N Engl J Med 2018; 378:1898.</a></li><li><a class="nounderline abstract_t">Schulz A, Specchio N, de Los Reyes E, et al. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study. Lancet Neurol 2024; 23:60.</a></li><li class="breakAll">BRINEURA (cerliponase alfa) injection for intraventricular use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761052s008lbl.pdf (Accessed on September 22, 2023).</li><li><a class="nounderline abstract_t">Schwering C, Kammler G, Wibbeler E, et al. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients. J Child Neurol 2021; 36:635.</a></li><li><a class="nounderline abstract_t">de Los Reyes E, Lehwald L, Augustine EF, et al. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. Pediatr Neurol 2020; 110:64.</a></li></ol></div><div id="topicVersionRevision">Topic 126618 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Beretning om et maerkeligt Sygdomstilfaelde hos fire Sødskende i Nærheden af Röraas</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cerebral degeneration with symmetrical changes in the maculae in two members of a family</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Über familiäre amaurotische Idiotien</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Über familiäre amaurotische Idiotie und verwandte Krankheitsbilder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dosud nepopsanýpripad familiárni amaurotickéidiotie komplikovanés hypoplasii mozeckovou</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Über spätinfantile familiäre amaurotische Idiotie mit Kleinhirnsymptonen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Über eine Spätform der amaurotischen Idiotie und ihre heredofamiliären Grundlagen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4121459" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infantile type of so-called neuronal ceroid-lipofuscinosis. 2. Morphological and biochemical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4698309" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Infantile type of so-called neuronal ceroid-lipofuscinosis. 1. A clinical study of 15 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528813" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The neuronal ceroid-lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528813" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The neuronal ceroid-lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22778232" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24619111" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29041969" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23919525" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Microglia in juvenile neuronal ceroid lipofuscinosis are primed toward a pro-inflammatory phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31678162" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathomechanisms in the neuronal ceroid lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Kufs disease due to mutation of CLN6: clinical, pathological and molecular genetic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27238410" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Correlation Among Genotype, Phenotype, and Histology in Neuronal Ceroid Lipofuscinoses: An Individual Patient Data Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24120650" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514215" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Loss of CLN7 results in depletion of soluble lysosomal proteins and impaired mTOR reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20680390" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12134079" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390177" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of the Lysosomal Membrane Protein, CLN3, in the Regulation of Cathepsin D Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/195436" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ultrastructural study of the vacuoles in the peripheral lymphocytes in juvenile amaurotic idiocy. Juvenile form of generalized ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37708259" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25962910" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cell biology of the NCL proteins: What they do and don't do.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30651094" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722572" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839750" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431521" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27125852" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lysosomal cathepsins and their regulation in aging and neurodegeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317235" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3284607" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kufs' disease: a critical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608501" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7668318" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neuronal ceroid-lipofuscinoses in Italy: an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374165" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular epidemiology of childhood neuronal ceroid-lipofuscinosis in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553520" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553520" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25976102" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23838030" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Classification and natural history of the neuronal ceroid lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7637805" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4371326" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Infantile type of so-called neuronal ceroid-lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/510322" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical, morphological, and biochemical investigations on a patient with an unusual form of neuronal ceroid-lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9664077" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular genetics of palmitoyl-protein thioesterase deficiency in the U.S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9535296" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Palmitoyl-protein thioesterase deficiency in a novel granular variant of LINCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261688" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adult neuronal ceroid lipofuscinosis caused by deficiency in palmitoyl protein thioesterase 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11506414" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440996" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582991" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Glycosaminoglycans modulate activation, activity, and stability of tripeptidyl-peptidase I in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12376936" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30119717" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30119717" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266810" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7668319" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Childhood neuronal ceroid-lipofuscinoses in Argentina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26224725" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : TPP1 deficiency: Rare cause of isolated childhood-onset progressive ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23418007" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20187884" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22013180" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167274" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Females experience a more severe disease course in Batten disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043799" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A clinical rating scale for Batten disease: reliable and relevant for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29392585" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Timing of cognitive decline in CLN3 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177590" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464428" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863828" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039534" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recognition and epileptology of protracted CLN3 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19489875" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28542676" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827497" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Novel CLN3 mutation causing autophagic vacuolar myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21820099" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22235333" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5132971" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A dominant form of neuronal ceroid-lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7133332" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A variant of Jansky-Bielschowsky disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20157158" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28542837" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25359263" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11791207" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549341" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528883" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965709" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297359" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15074367" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201763" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28586915" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Specific Alleles of CLN7/MFSD8, a Protein That Localizes to Photoreceptor Synaptic Terminals, Cause a Spectrum of Nonsyndromic Retinal Dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34201538" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : CLN8 Mutations Presenting with a Phenotypic Continuum of Neuronal Ceroid Lipofuscinosis-Literature Review and Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589000" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Turkish variant late infantile neuronal ceroid lipofuscinosis (CLN7) may be allelic to CLN8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220808" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Variant late-infantile neuronal ceroid lipofuscinosis due to a novel heterozygous CLN8 mutation and de novo 8p23.3 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570191" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: Another genetic hit in the Mediterranean.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073227" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Northern epilepsy, a new member of the NCL family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15024724" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349861" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23160995" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685649" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cathepsin D deficiency is associated with a human neurodegenerative disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25298308" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31855245" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8085432" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15986421" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21316993" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Juvenile parkinsonism associated with heterozygous frameshift ATP13A2 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16964263" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388936" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274848" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748208" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22693283" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000449" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Management of CLN1 Disease: International Clinical Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948513" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The epidemiology of progressive intellectual and neurological deterioration in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30337492" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764178" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnostic approach to childhood-onset cerebellar atrophy: a 10-year retrospective study of 300 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439737" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Rett-like onset in late-infantile neuronal ceroid lipofuscinosis (CLN7) caused by compound heterozygous mutation in the MFSD8 gene and review of the literature data on clinical onset signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157020" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Comprehensive evaluation of the child with intellectual disability or global developmental delays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30919832" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Evaluation of the child with global developmental delay and intellectual disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29054862" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Current evidence-based recommendations on investigating children with global developmental delay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457518" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Systematic review of MRI findings in children with developmental delay or cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27765741" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : MRI Brain Volume Measurements in Infantile Neuronal Ceroid Lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15002049" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8837098" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17334752" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Decreased T2 signal in the thalami may be a sign of lysosomal storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042927" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Assessment of disease severity in late infantile neuronal ceroid lipofuscinosis using multiparametric MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29853519" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Global and Widespread Local White Matter Abnormalities in Juvenile Neuronal Ceroid Lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553878" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31597037" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26846731" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A girl with infantile neuronal ceroid lipofuscinosis caused by novel PPT1 mutation and paternal uniparental isodisomy of chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778029" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Late-onset childhood neuronal ceroid lipofuscinosis: Early clinical and electroencephalographic markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632327" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602993" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : NCL diseases - clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647346" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19353721" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Dystonic storm due to Batten's disease treated with pallidotomy and deep brain stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589001" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Cardiac pathology in neuronal ceroid lipofuscinoses--a clinicopathologic correlation in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221116" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Progressive conduction defects and cardiac death in late infantile neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182766" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Neuronal ceroid lipofuscinosis with severe biventricular impairment: a rare genetic disorder with associated myopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24997880" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29923092" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21556831" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Parent-reported benefits of flupirtine in juvenile neuronal ceroid lipofuscinosis (Batten disease; CLN3) are not supported by quantitative data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10191137" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Melatonin ineffective in neuronal ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms recorded by wrist actigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2486154" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6288303" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23581634" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378887" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33882967" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31884868" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31884868" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688815" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Study of Intraventricular Cerliponase Alfa for CLN2 Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38101904" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38101904" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33543660" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32684372" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
